|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Post‐liver transplantation sarcopenia in cirrhosis: A prospective evaluation显示文摘 | Cynthia Tsien Ari Garber Arvind Narayanan Shetal N Shah David Barnes Bijan Eghtesad John Fung Arthur J McCullough Srinivasan Dasarathy | 2014 | J Gastroenterol Hepatol2014，，6： | 2 |
| 2 | Technological status of plasma-deposited thin-film silicon photovoltaics显示文摘 | Arvind Shah Etienne Moulin Christophe Ballif | 2013 | Solar Energy Materials and Solar Cells2013，，： | 2 |
| 3 | The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years显示文摘有年龄的背景冠的心疾病(CHD ) 风险增加;然而类脂化合物阴沉的治疗是显著地在病人的 under-utilized > 65 年。目的是评估安全,在更老的病人的类脂化合物阴沉的治疗的功效与 atorvastatin 对待 10 mg + ezetimibe 10 mg (EZ/Atorva ) 对增加 atorvastatin 剂量到 40 mg。方法病人有动脉粥样硬化患者的 65 年脉管的疾病(LDL-C 1.81 mmol/L ) 或在为冠的心的高风险,疾病(LDL-C 2.59 mmol/L ) 为 12 wk 对 uptitration 被使随机化到 EZ/Atorva 到为 6 wk 的 20 mg 由 atorvastatin 跟随了的 atorvastatin 为 6 wk 的 40 mg。在完成 prespecified LDL-C 层次的 LDL-C 和另外的类脂化合物参数和百分比病人的百分比变化在 12 wk 以后被估计。结果 EZ/Atorva 在病人在大多数类脂化合物参数对 atorvastatin 的 uptitration 生产了更大的减小 75 年(n = 228 ) ,与病人通常一致 6574 年(n = 812 ) 。更多的病人在 6 wk 并且在病人在两个年龄组与联合治疗对 monotherapy 完成了 LDL-C 目标在 12 wk 的 75 年。在 12 wk,更多的病人 75 年与 monotherapy 对联合治疗完成了 LDL-C 目标。EZ/Atorva 在大多数类脂化合物生产了更有利的改进对加倍或 quadrupling 在病人的 atorvastatin 剂量 75 年,与在病人的调查结果通常一致 6574 年。我们的结果扩大了证明 ezetimibe 增加了 statin 的以前的调查结果的结论为在病人改进类脂化合物侧面提供了一种通常容忍得好的治疗学的选择 65 ~ 74 年和 75 岁。 | Ori Ben-Yehuda Nanette K. Wenger Christian Constance Franklin Zieve Mary E. Hanson Jian-Xin Lin Arvind K. Shah Charlotte Jones-Burton Andrew M. Tershakovec | 2011 | Journal of Geriatric Cardiology2011，8，1： | 2 |
| 4 | Preoperative embolization of primary bone tumors:A case control study显示文摘AIM:To study the safety and effectiveness of preoperative embolization of primary bone tumors in relation to intraoperative blood loss,intraoperative blood transfusion volume and surgical time.METHODS:Thirty-three patients underwent preoperative embolization of primary tumors of extremities,hip or vertebrae before resection and stabilization.The primary osseous tumors included giant cell tumors,aneurysmal bone cyst,osteoblastoma,chondroblastoma and chondrosarcoma.Twenty-six patients were included for the statistical analysis(embolization group)as they were operated within 0-48 h within preoperative embolization.A control group(non-embolization group,n = 28)with bone tumor having similar histological diagnosis and operated without embolization was retrieved from hospital record for statistical comparison.RESULTS:The mean intraoperative blood loss was 1300 mL(250-2900 mL),the mean intraoperative blood transfusion was 700 m L(0-1400 m L)and the mean surgical time was 221 ± 76.7 min for embolization group(group Ⅰ,n = 26).Non-embolization group(group Ⅱ,n = 28),the mean intraoperative blood loss was 1800 m L(800-6000 m L),the mean intraoperative blood transfusion was 1400 mL(700-8400 mL)and the meansurgical time was 250 ± 69.7 min.On comparison,statistically significant(P < 0.001)difference was found between embolisation group and non-embolisation group for the amount of blood loss and requirement of blood transfusion.There was no statistical difference between the two groups for the surgical time.No patients developed any angiography or embolization related complications.CONCLUSION:Preoperative embolization of bone tumors is a safe and effective adjunct to the surgical management of primary bone tumors that leads to reduction in intraoperative blood loss and blood transfusion volume. | Roushan Jha Raju Sharma Shishir Rastogi Shah Alam Khan Arvind Jayaswal Shivanand Gamanagatti | 2016 | World Journal of Radiology2016，8，4： | 1 |
| 5 | Microcrystalline silicon and 'micromorph' tandem solar cells 显示文摘 | Arvind Shah Meier J Vallat-Sauvain E | 2002 | Thin Solid Films2002，，： | 1 |
| 6 | Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy显示文摘 | Thomas A. Pearson Christie M. Ballantyne Enrico Veltri Arvind Shah Steven Bird Jianxin Lin Elizabeth Rosenberg Andrew M. Tershakovec | 2009 | The American Journal of Cardiology2009，，3： | 1 |
| 7 | Microcrystalline Silicon and Micromorph Tandem Solar Cells 显示文摘 | Arvind Shah Meier J Vallat-Sauvain E | 2002 | Thin Solid Films2002，3404，： | 1 |
| 8 | Microcrystalline Silicon and 'Micrornorph' Tandem Solar Cells显示文摘 | ARVIND Shah MEIER J VALLAT--Sauvain E | 2002 | Thin Solid Films2002，403，17： | 1 |
| 9 | Microcrystalline silicon and micromorph'tandem solar cells 显示文摘 | Arvind Shah Meier J Vallat- Sauvain E etal | 2002 | Thin Solid Films2002，，： | 1 |
| 10 | Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non–HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes显示文摘 | Ruth S. Weinstock Ronald B. Goldberg John R. Guyton Theodore Mazzone Adam Polis Joanne E. Tomassini Jianxin Lin Arvind Shah Andrew M. Tershakovec | 2008 | Journal of Clinical Lipidology2008，，1： | 1 |
| 11 | Improving outcomes from acute kidney injury: report of an initiative显示文摘 | Arvind Bagga Aysin Bakkaloglu Prasad Devarajan Ravindra L. Mehta John A. Kellum Sudhir V. Shah Bruce A. Molitoris Claudio Ronco David G. Warnock Michael Joannidis Adeera Levin | 2007 | Pediatric Nephrology2007，，10： | 1 |
| 12 | A Comprehensive Transcriptome Assembly of Pigeonpea (Cajanus cajan L.) using Sanger and Second-Generation Sequencing Platforms显示文摘为 pigeonpea 的一个全面 transcriptome 集会被分析 IIx 单个结束读的 1.289 亿短 Illumina GA 开发了,结束 FLX/454 读的 219 万个单身者,和表示的 18353 Sanger 从超过 16 遗传型定序标签。结果的 transcriptome 集会,把 v2 叫作 CcTA,与 1510bp 的 N50 包括了 21434 抄本集会 contigs (TAC ) ,最大的 8kb。21434 TAC,(77.5%) 16622 能被印射在上在相当紧的排列参数下面造 1.0.9 到大豆染色体。基于 intron 连接的知识, 10009 教材对为放大跨越区域(ISR ) 的 intron 从 5033 TAC 被设计。由在作为一本参考书在大豆染色体上 pigeonpea 的 BAC-end-derived SSR loci 印射的 silico 使用,在染色体水平的通常认为的印射位置为 6284 个 ISR 标记被预言,盖住所有 11 个 pigeonpea 染色体。128 个 ISR 标记的一个子集在一套八遗传型上被分析。当 116 个标记被验证时, 70 个标记显示出一~三等位基因,与 0.16 多型性信息内容(照片) 的一般水准价值。在摘要, CcTA v2 抄本汇编和 ISR 标记将用作一个有用资源在 pigeonpea 加速基因研究和繁殖应用程序。 | Himabindu Kudapa Arvind K. Bharti Steven B. Cannon Andrew D. Farmer Benjamin Mulaosmanovi Robin Kramer Abhishek Bohra Nathan T. Weeks John A. Crow Reetu Tuteja Trushar Shah Sutapa Dutta Deepak K. Gupta Archana Singh Kishor Gaikwad Tilak R. Sharma Gregory D. May Nagendra K. Singh Rajeev K. Varshney | 2012 | Molecular Plant2012，5，5： | 0 |
| 13 | Intradermal fillers for minimally invasive treatment of facial aging显示文摘The ever-increasing interest in retaining a youthful physical appearance has facilitated the development of various minimally invasive dermatological techniques.The use of intradermal fillers can be incorporated into dermatological practices with minimal overhead costs.This strategy addresses facial volume loss and dynamic lines,which are the main features of facial aging.Moreover,intradermal fillers provide an array of flexible treatment options for a balanced and holistic result to dermatological practitioners.This paper reviews the different intradermal fillers categorized by biodegradable and non-permanent fillers including collagen based materials,hyaluronic acid and autologous fat,semi-permanent fillers including poly methyl methacrylate,poly-L-lactic acid and calcium hydroxyapatite microspheres,and permanent fillers including silicone.A discussion is provided of the commercial products made of these materials and their clinical efficacy in the treatment of facial aging. | Zhi Yuan(William)Lin Vishva Shah Arvind Dhinakar Lara Yildirimer Wen-Guo Cui Xin Zhao | 2016 | Plastic and Aesthetic Research2016，3，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员